CL2012002306A1 - Procedimiento para producir un conjugado de biomoleculas porque comprende las etapas de activar la biomolecula por contacto con un agente activador; retirar el agente activador; y conjugar el agente activador; y conjugar la biomolecula haciendo reaccionar la biomolecula con un polimero activado - Google Patents

Procedimiento para producir un conjugado de biomoleculas porque comprende las etapas de activar la biomolecula por contacto con un agente activador; retirar el agente activador; y conjugar el agente activador; y conjugar la biomolecula haciendo reaccionar la biomolecula con un polimero activado

Info

Publication number
CL2012002306A1
CL2012002306A1 CL2012002306A CL2012002306A CL2012002306A1 CL 2012002306 A1 CL2012002306 A1 CL 2012002306A1 CL 2012002306 A CL2012002306 A CL 2012002306A CL 2012002306 A CL2012002306 A CL 2012002306A CL 2012002306 A1 CL2012002306 A1 CL 2012002306A1
Authority
CL
Chile
Prior art keywords
biomolecule
conjugate
activating agent
activating
reacting
Prior art date
Application number
CL2012002306A
Other languages
English (en)
Inventor
Jens H Vogel
Chi Shung Brian To
Carolina Lucia Bianco
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CL2012002306A1 publication Critical patent/CL2012002306A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/02—Reverse osmosis; Hyperfiltration ; Nanofiltration
    • B01D61/025—Reverse osmosis; Hyperfiltration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/10—Cross-flow filtration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Water Supply & Treatment (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

Procedimiento para producir un conjugado de biomoléculas porque comprende las etapas de activar la biomolécula por contacto con un agente activador; retirar el agente activador; y conjugar el agente activador; y conjugar la biomolécula haciendo reaccionar la biomolécula con un polímero activado.
CL2012002306A 2010-02-21 2012-08-20 Procedimiento para producir un conjugado de biomoleculas porque comprende las etapas de activar la biomolecula por contacto con un agente activador; retirar el agente activador; y conjugar el agente activador; y conjugar la biomolecula haciendo reaccionar la biomolecula con un polimero activado CL2012002306A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30651310P 2010-02-21 2010-02-21

Publications (1)

Publication Number Publication Date
CL2012002306A1 true CL2012002306A1 (es) 2013-01-18

Family

ID=44483343

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002306A CL2012002306A1 (es) 2010-02-21 2012-08-20 Procedimiento para producir un conjugado de biomoleculas porque comprende las etapas de activar la biomolecula por contacto con un agente activador; retirar el agente activador; y conjugar el agente activador; y conjugar la biomolecula haciendo reaccionar la biomolecula con un polimero activado

Country Status (35)

Country Link
US (1) US9254336B2 (es)
EP (1) EP2536399B1 (es)
JP (1) JP5726915B2 (es)
KR (1) KR101776976B1 (es)
CN (2) CN102970988B (es)
AU (1) AU2011217794B2 (es)
BR (1) BR112012020855B8 (es)
CA (1) CA2790401C (es)
CL (1) CL2012002306A1 (es)
CO (1) CO6592111A2 (es)
CR (1) CR20120437A (es)
CU (1) CU20120121A7 (es)
CY (1) CY1122711T1 (es)
DK (1) DK2536399T3 (es)
EA (1) EA201290804A1 (es)
EC (1) ECSP12012112A (es)
ES (1) ES2769629T3 (es)
GT (1) GT201200244A (es)
HK (2) HK1182330A1 (es)
HR (1) HRP20192164T1 (es)
HU (1) HUE047661T2 (es)
IL (1) IL221447A (es)
LT (1) LT2536399T (es)
MX (1) MX2012009674A (es)
NZ (1) NZ601905A (es)
PE (1) PE20130003A1 (es)
PH (1) PH12016501602A1 (es)
PL (1) PL2536399T3 (es)
PT (1) PT2536399T (es)
RS (1) RS59827B1 (es)
SG (1) SG183309A1 (es)
SI (1) SI2536399T1 (es)
UA (1) UA115221C2 (es)
WO (1) WO2011103531A1 (es)
ZA (2) ZA201206215B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE481323A (es) * 1947-04-10
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
RU2016122041A (ru) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
CA2932476A1 (en) 2013-12-12 2015-06-18 Stemcentrx, Inc. Novel anti-dpep3 antibodies and methods of use
JP2017514143A (ja) 2014-02-21 2017-06-01 アッヴィ・ステムセントルクス・エル・エル・シー メラノーマに使用するための抗ｄｌｌ３抗体および薬物コンジュゲート
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384909B2 (en) * 2002-07-15 2008-06-10 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
BR0312692A (pt) * 2002-07-15 2007-06-26 Univ Texas anticorpos selecionados e peptìdeos de duramicina que se ligam a fosfolipìdios aniÈnicos e aminofosfolipìdios e seus usos no tratamento de infecções virais e cáncer
CA2509260C (en) 2002-12-31 2012-10-02 Nektar Therapeutics Al, Corporation Maleamic acid polymer derivatives and their bioconjugates
US20050175619A1 (en) * 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
PL1824988T3 (pl) * 2004-11-12 2018-01-31 Bayer Healthcare Llc Ukierunkowana na miejsce modyfikacja czynnika VIII
US20070173634A1 (en) * 2006-01-24 2007-07-26 Olsson Nils U Methods for one-step purification of organic polymers using tangential flow filtration
US20080220448A1 (en) * 2006-09-01 2008-09-11 Blincko Stuart J Antigenic protein conjugates and process for preparing same
US8207298B2 (en) * 2008-05-01 2012-06-26 Archemix Corp. Methods of separating biopolymer conjugated molecules from unconjugated molecules
ES2597954T3 (es) * 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
NZ629256A (en) * 2009-12-22 2016-02-26 Celldex Therapeutics Inc Vaccine compositions

Also Published As

Publication number Publication date
UA115221C2 (uk) 2017-10-10
IL221447A0 (en) 2012-10-31
CA2790401A1 (en) 2011-08-25
US20130040362A1 (en) 2013-02-14
CU20120121A7 (es) 2013-01-30
BR112012020855B8 (pt) 2021-05-25
EP2536399A1 (en) 2012-12-26
CN102970988A (zh) 2013-03-13
JP5726915B2 (ja) 2015-06-03
NZ601905A (en) 2014-09-26
EP2536399B1 (en) 2019-11-20
EA201290804A1 (ru) 2013-03-29
PT2536399T (pt) 2020-02-06
CR20120437A (es) 2012-12-07
CN102970988B (zh) 2016-03-16
PH12016501602A1 (en) 2017-06-05
KR101776976B1 (ko) 2017-09-08
HUE047661T2 (hu) 2020-05-28
PE20130003A1 (es) 2013-01-19
GT201200244A (es) 2014-09-02
LT2536399T (lt) 2020-03-10
ECSP12012112A (es) 2012-10-30
CN105664175A (zh) 2016-06-15
JP2013520441A (ja) 2013-06-06
AU2011217794B2 (en) 2015-01-29
CN105664175B (zh) 2019-07-23
DK2536399T3 (da) 2020-02-10
WO2011103531A1 (en) 2011-08-25
HK1225652A1 (zh) 2017-09-15
ZA201405941B (en) 2018-05-31
BR112012020855B1 (pt) 2021-05-04
RS59827B1 (sr) 2020-02-28
CY1122711T1 (el) 2021-03-12
SG183309A1 (en) 2012-09-27
ZA201206215B (en) 2014-10-29
MX2012009674A (es) 2012-09-07
CO6592111A2 (es) 2013-01-02
PL2536399T3 (pl) 2020-06-29
US9254336B2 (en) 2016-02-09
ES2769629T3 (es) 2020-06-26
HK1182330A1 (zh) 2013-11-29
IL221447A (en) 2015-09-24
HRP20192164T1 (hr) 2020-03-06
KR20120120966A (ko) 2012-11-02
CA2790401C (en) 2018-05-29
AU2011217794A1 (en) 2012-09-20
BR112012020855A2 (pt) 2017-08-29
EP2536399A4 (en) 2016-02-24
SI2536399T1 (sl) 2020-02-28

Similar Documents

Publication Publication Date Title
CL2012002306A1 (es) Procedimiento para producir un conjugado de biomoleculas porque comprende las etapas de activar la biomolecula por contacto con un agente activador; retirar el agente activador; y conjugar el agente activador; y conjugar la biomolecula haciendo reaccionar la biomolecula con un polimero activado
BRPI0923037A2 (pt) método para produzir lentes de contato de hidrogel de silicone
BR112014005298A2 (pt) método para produzir polímero á base de dieno conjugado modificado, polímero á base de dieno conjugado modificado, composição de polímero á base de dieno conjugado modificado, composição de borracha, e, pneumático
BRPI1008021A2 (pt) Método para fabricação de 2,6-dioxabiciclo-(3.3.0)-octano-4,8-diona
AR089466A1 (es) Hidrogeles de silicona que tienen una estructura formada mediante cinetica de reaccion controlada
ECSP13012393A (es) Un agente de sostén
CL2014001963A1 (es) Anticuerpo contra la molecula de guia repulsiva (rgma); composición que la comprende y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas.
BRPI0923797A2 (pt) Método para produzir um éster.
BR112013006817A2 (pt) método, casquilho e casquilho formado pelo método
BRPI1008453A2 (pt) microestruturas de relevo de superfície, dispositivos relacionados e método de fazer as mesmas
BRPI0923407A2 (pt) veículo, e, método para resfriar uma cvt de um veículo.
BR112012002746A2 (pt) método para produção de copolímero
BR112012005376A2 (pt) agente de modificação, método para produzir polímero de dieno conjugado modificado utilizando agente de modificação e polímero de dieno conjugado modificado.
BRPI0923801A2 (pt) Métodos para produzir um éster, e para produzir amidas.
BR112012019778A2 (pt) dispositivo de produção de hidrogênio e método para produzir hidrogênio
BRPI0909122A2 (pt) métodos para produzir produtos estiráveis.
BRPI1011186A2 (pt) contas expandíveis, corpo moldado, e, método de produção para o mesmo
BRPI1014881A2 (pt) película antirreflexo, método para manufaturar película antirreflexo, e aparelho de exibição."
BRPI1014059A2 (pt) Espumas grossas para aplicações biomédicas e métodos de fabricação.
BR112012003685A2 (pt) método para fabricar pneu de base, dispositivo de vulcanização e pneu de base
ES2666382T8 (es) Ortesis activa para la rehabilitación neurológica del movimiento de los miembros inferiores, sistema que comprende dicha órtesis y proceso para poner en funcionamiento dicho sistema
ECSP11011518A (es) Procedimiento para producir derivados de piripiropeno
BRPI0915080A2 (pt) dispositivos, processos e métodos para a produção de ésteres de alquílicos inferiores
ECSP12012203A (es) Procedimiento para producir derivados de piripiropeno
CL2014000451A1 (es) Metodo para sedar, anestesiar o someter a eutanasia un organismo acuático que comprende poner en contacto dicho organismo con linalol; composición que comprende linalol y al menos un solvente o surfactante.